Phase 2 N=40 A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Ovarian Clear Cell Carcinoma
Primary: Six Month Progression Free Survival Rate — 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Ovarian Clear Cell Cystadenocarcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Proportion of Patients Who Are Alive and Progression-free for at Least 12 Months After Study Entry in Patients With Newly Diagnosed Stage III or IV Clear Cell Ovarian…
Phase 2 N=35 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
Ovarian Clear Cell Adenocarcinoma · Recurrent Ovarian Carcinoma
Primary: Objective Tumor Response Rate (Complete and Partial Response) — 6.7 percentage of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Phase 2 N=59 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=56 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Brenner Tumor · Fallopian Tube Cancer · Ovarian Clear Cell Cystadenocarcinoma
Primary: Pathologic Complete Response Rates — 8 participants
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=95 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Phase 2 N=38 Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Phase 2 N=47 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Primary Peritoneal Serous Adenocarcinoma · Recurrent Ovarian Epithelial Cancer
Primary: Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in…
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Phase 2 N=55 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants
Phase 2 N=14 Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
Malignant Ovarian Clear Cell Tumor · Recurrent Ovarian Carcinoma
Primary: Complete or Partial Objective Tumor Response — 3 Participants
Phase 2 N=20 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 1.7 months
Phase 2 N=24 Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Best Overall Response and Objective Response Rate Following Treatment With CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or…
Phase 2 N=29 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Phase 2 N=31 Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recurrent Epithelial Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer
Primary: Overall Response Rate (ORR) — 4 participants
Phase 2 N=36 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Overall Response Rate — .083 proportion of participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=247 p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
Phase 2 N=44 Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants
Phase 2 N=15 A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Ovarian Cancer
Primary: Part 2: Median Progression-free Survival (PFS) in Weeks Based on Enhanced Response Evaluation Criteria In Solid Tumors Version 1.1 (Enhanced RECIST 1.1) by Independent…
Phase 2 N=122 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Phase 2 N=23 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Recurrent Ovarian Cancer · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants
Phase 2 N=60 Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: 6 Month Progression-free Survival (PFS) — 13 participants
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2